About human plasma coagulation factor xiii
Plasma-derived coagulation factor XIII
Used for
- Prevention and treatment of bleeding in congenital factor XIII deficiency
- Treatment of acquired factor XIII deficiency when clinically indicated
Usual adult dose
Congenital deficiency: usually 10 IU/kg intravenously every 28 days; adjust using factor XIII activity levels.
Usual dose in children
Congenital deficiency: usually 10 IU/kg intravenously every 28 days; adjust using factor XIII activity levels.
Common side effects
- Allergic or infusion reactions
- Fever
- Headache
- Rarely, blood clots or development of inhibitors
Important warnings
- Use under specialist supervision; monitor factor XIII activity.
- Severe allergic reactions can occur.
- Thrombosis is possible, especially with excessive factor XIII levels.
- Contains plasma-derived proteins; residual infectious-agent risk cannot be completely excluded.
Pregnancy
Limited information; use when clearly needed, with specialist oversight.
Breastfeeding
Limited information; use when clearly needed, with specialist oversight.
Interactions
- No established clinically significant drug interactions; tell clinicians about all medicines and clotting treatments.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.